Adma Biologics (ADMA) Change in Receivables (2011 - 2025)
Adma Biologics' (ADMA) quarterly Change in Receivables came in at $20.8 million in Q4 2025, up 14820.57% YoY from N/an in Q4 2024, and down 25.73% on a QoQ basis from $27.9 million in Q3 2025.
Adma Biologics (ADMA) Change in Receivables (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Change in Receivables data on file, last reported at $20.8 million in Q4 2025.
- Quarterly Change in Receivables rose 14820.57% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $108.4 million (up 380.25% YoY) and the FY2025 annual result came in at $108.4 million, up 380.25% from the prior year.
- Change in Receivables eased to $20.8 million in Q4 2025, from $27.9 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $49.4 million in Q1 2025 to a low of -$19.5 million in Q2 2024.
- A 5-year average of $7.3 million and a median of $5.2 million in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2021 — Change in Receivables plunged 1654.71% — and 2025, when it jumped 14820.57%.
- Tracing ADMA's Change in Receivables over 5 years: stood at $8.2 million in 2021, then sank by 165.95% to -$5.4 million in 2022, then advanced by 27.78% to -$3.9 million in 2023, then soared by 96.38% to -$141000.0 in 2024, then jumped by 14820.57% to $20.8 million in 2025.
- The last three Change in Receivables figures came in at $20.8 million (Q4 2025), $27.9 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.76 Mn |
| Dec 31, 2025 | 20.76 Mn |
| Sep 30, 2025 | 27.95 Mn |
| Sep 30, 2025 | 27.95 Mn |
| Jun 30, 2025 | 10.31 Mn |
| Jun 30, 2025 | 10.31 Mn |
| Mar 31, 2025 | 49.41 Mn |
| Mar 31, 2025 | 49.41 Mn |
| Dec 31, 2024 | -141,000.00 |
| Dec 31, 2024 | -141,000.00 |
| Sep 30, 2024 | 20.03 Mn |
| Sep 30, 2024 | 20.03 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Mar 31, 2024 | 22.20 Mn |
| Mar 31, 2024 | 22.20 Mn |
| Dec 31, 2023 | -3.90 Mn |
| Dec 31, 2023 | -3.90 Mn |
| Sep 30, 2023 | -5.41 Mn |
| Sep 30, 2023 | -5.41 Mn |